Clinical trial · Interventional
The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract
Single-centre Prospective Study on the Identification of Clinical, Laboratory, Anatomopathological and Molecular Characteristics for the Future Management of Patients With Neoplasms of the Gastro-intestinal Tract
NCT06728358CI-TRIAL-00094128SOCRATEactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the present study is to research histological and molecular markers in patients with neoplasia of the gastrointestinal tract.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular analyses | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients undergoing molecular analysis
- description
- Patients undergoing molecular analysis
- interventionNames
- Diagnostic Test: Molecular analyses
Primary outcomes (1)
- measure
- Overall Survival
- timeFrame
- 48 months
- description
- The primary objective of the study is to evaluate the probabilitỳ of survival in terms of OS in relation to the expression of specific anatomopathological, immunohistochemical and molecular markers (GATA6, GemPred Molecular Signature and FOLFIRINOX Molecular Signature) present in the tumour tissue of patients with neoplasms of the gastro-enteric district in the setting of resectable/metastatic disease.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older; * PS ECOG 0-2; * Histological diagnosis of cancer of the gastro-enteric district: intestinal, pancreatic, biliary tract neoplasms; * Radiological evidence of resectable/locally advanced/metastatic disease on the date of the first visit; * Availability of tumour histological material; * At least one visit following the first oncological visit. Exclusion Criteria: * Absence of histological diagnosis of neoplasm of the gastro-enteric tract; * Lack of histological specimens on which to perform examinations.
References
Publications (0)
Data not yet available
No reference posted for this study.